anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/NL91/00013 Sec. 371 Date Aug. 24, 1993 Sec. 102(e) Date Aug. 24, 1993 PCT Filed Jan. 30, 1991 PCT Pub. No. WO91/11176 PCT Pub. Date Aug. 8, 1991.An article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances, which wall is made using a biodegradable polymeric material permeable to the active substance, wherein the wall is composed mainly of a combination of at least two different polymeric materials in which one polymeric material is permeable to the active substance and is degradable and the other polymeric material is relatively poorly permeable to the active substance and is degradable and the conveyor path for the delivery of the active substance from the hollow space to the surroundings of the article is a continuous distance leading at least through the polymeric material permeable to the active substance.
The experimental procedure for each participant assume random blind acute ingestion of placebo (PLA) at one of the study visits, which will be separated from other study visits with 7-days wash-out. The PLA preparation will be provided in the form of powder and dissolved in 200 mL of water. PLA will be ingested within up to 5 minutes. The ingestion will take place 60 minutes before the test exercise.
All patients in the study have a 4 weeks period of 500 mg methylprednisolone iv/week. Depending of the response patients are classified as non- responders (and are given RTX and MTX) or responders. The responders continue with intravenous infusion of Methylprednisolone 500 mg /week in 2 weeks and thereafter 250 mg iv/week in 6 weeks.
The present invention relates to a cosmetic composition containing hydrolyzed sponge powder or sponge powder. More specifically, the present invention relates to a cosmetic composition having a rapid skin regeneration function and a scalp improvement function by encapsulating and stabilizing hydrolyzed sponge powder or sponge spicule powder in a lamellar liquid crystal. According to the present invention, hydrolyzed sponge powder or sponge powder is encapsulated in a lamellar liquid crystal, and an extract for minimizing damage occurring during the penetration of hydrolyzed sponge powder or sponge powder into the stratum corneum is encapsulated together. Thus, a rapid skin regeneration function and a scalp improvement function can be exhibited. In addition, the cosmetic composition containing hydrolyzed sponge powder or sponge powder according to the present invention has excellent effects in skin moisturizing, skin elasticity, skin whitening, and skin wrinkle alleviation, and thus can be applied to various formulations (cream, essence, and the like). Moreover, the cosmetic composition containing hydrolyzed sponge powder or sponge powder according to the present invention has excellent effects in alleviating scalp sebum, enhancing scalp pore size, improving the number of hairs, and alleviating hair cuticles, and thus can be applied to various scalp cosmetic products (a toner, an essence, a shampoo, and the like).
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to novel and early unknown form of ranitidine hydrochloride showing property of H 2 -blocking agent. Invention relates to roentgen-amorphous form of ranitidine. Roentgen-amorphous form is physically stable and invention describes also method for preparing roentgen-amorphous form from its early known crystalline modifications. Invention provides preparing a novel roentgen-amorphous form of ranitidine hydrochloride showing the enhanced specific antiulcer activity. EFFECT: improved preparing method, valuable medicinal properties. 12 cl, 2 dwg, 1 tbl
In recent years, molecular biology-based diagnostic techniques have made remarkable strides and are now extensively utilized in clinical practice, providing invaluable insights for disease diagnosis and treatment. However, forensic medicine, especially forensic pathology, has witnessed relatively limited progress in the application of molecular biology technologies. A significant challenge in employing molecular techniques for forensic diagnoses lies in the quantitative and qualitative changes observed in diagnostic markers due to sample degradation-a recognized and formidable obstacle. Inspired by the success of DNA sequencing in forensic practices, which enables accurate individual identification even in cases involving degraded and deteriorated tissues and organs, we propose the application of the assay for transposase-accessible chromatin with sequencing (ATAC-seq) to identify targets at the transcriptional onset, exploring chromatin and DNA-level alterations for injury and disease inference in forensic samples. This study employs ATAC-seq to explore alterations in chromatin accessibility post-injury and their subsequent changes over a 2-h degradation period, employing traumatic brain injury (TBI) as a representative model. Our findings reveal high sensitivity of chromatin accessibility sites to injury, evidenced by shifts in thousands of peak positions post-TBI. Remarkably, these alterations remain largely unaffected by early degradation. Our results robustly endorse the notion that integrating and incorporating these specific loci for injury and disease diagnosis in forensic samples holds tremendous promise for practical application. We further validated the above results using human cortical tissue, which supported that early degradation did not significantly affect chromatin accessibility. This pioneering advancement in molecular diagnostic techniques may revolutionize the field of forensic science, especially forensic pathology.
Potassium is a shortfall nutrient according to the 2010 Dietary Guidelines for Americans. Only 3% of Americans meet the recommended Adequate Intake of 4700 mg/d for potassium. Average potassium intake is approximately half of the Recommended Dietary Allowance (RDA), with potatoes providing the highest percentage (19-20% of potassium) in the American diet. Recommended dietary potassium intakes were determined primarily to optimize protection against hypertension and secondarily to protect against stroke and coronary heart disease. In setting requirements for most minerals, bioavailability is usually considered. However, little is known about bioavailability of potassium and what is known is from supplements rather than food. Recently, we performed a potassium bioavailability study on white potatoes looking at 35 healthy, normotensive men and women at 3 levels of potassium intake as potatoes or potassium gluconate supplements. Bioavailability of potassium was determined from AUC of serial blood draws and cumulative urinary excretion. Serum potassium Area Under the Curve (AUC )increased with dose (P\<0.0001) and did not differ due to source (p=0.52). Cumulative 24 h urinary potassium also increased with dose (p\<0.0001) and was greater with potato than supplement (p\<0.0001), concluding that bioavailability of potassium is as high from potatoes as from supplements. These data allow us to evaluate the quality of the food as a source of potassium. However, a remaining question is whether retention of potassium from potatoes is higher than from the salt, which requires a metabolic balance study to determine. The effects of potassium rich foods on blood pressure have also been recently accessed. A controlled feeding study would properly capture potassium retention and balance, as well as adequately control for any positive benefit potassium may have on blood pressure and other vascular outcomes.

Increasing potassium citrate decreased titratable acidity and improved calcium retention in a dose response manner in postmenopausal women. There is one Randomized Controlled Trial (RCT) of potassium on bone, in postmenopausal women, showing a benefit of a supplement of potassium chloride on protecting against bone loss. Similar studies have not been performed with food sources of potassium.

This study is designed to evaluate the effect of added potassium (K) from potatoes in the diet on K retention , blood pressure, and parameters related to bone health including calcium retention and acid base balance.
Due to the increased likelihood of allergic reactions in atopic patients, it is important that a complete history of known and suspected allergies as well as allergic-like symptoms, e.g., rhinitis, bronchial asthma, eczema and urticaria, be obtained prior to any medical procedure utilizing these products. A mild allergic reaction would most likely include generalized pruritus, erythema or urticaria (approximately 1 in 250,000). Such reactions will generally respond to an antihistamine such as 50 mg of diphenhydramine or its equivalent. In the rarer, more serious reactions (approximately 1 in 1,000,000) laryngeal edema, bronchospasm or hypotension could develop. Severe reactions which may require emergency measures are often characterized by peripheral vasodilation, hypotension, reflex tachycardia, dyspnea, agitation, confusion and cyanosis, progressing to unconsciousness. Treatment should be initiated immediately with 0.3 to 0.5 cc of 1:1000 epinephrine subcutaneously. If bronchospasm predominates, 0.25 to 0.50 grams of intravenous aminophylline should be given slowly. Appropriate vasopressors might be required. Adrenocorticosteroids, even if given intravenously, exert no significant effect on the acute allergic reactions for a few hours. The administration of these agents should not be regarded as emergency measures for the treatment of allergic reactions. Apprehensive patients may develop weakness, pallor, tinnitus, diaphoresis and bradycardia following the administration of any diagnostic agent. Such reactions are usually non-allergic in nature and are best treated by having the patient lie flat for an additional 10 to 30 minutes under observation.
Information regarding the genetic alterations in extramammary Paget disease (EMPD) is scarce. This study investigated the significance of CDKN2A and MTAP alterations in EMPD progression using immunohistochemistry and panel DNA sequencing. In total, 24 invasive/metastatic EMPD cases were included in this study. The immunoexpression of p16 and MTAP in the primary in situ, primary invasive, and metastatic tumor components was evaluated. Panel DNA sequencing was performed for metastatic tumor components in 5 of the 24 cases. Immunoexpression of p16 in the in situ tumor component was at least partially preserved in all 19 tested cases (100%). By contrast, the invasive tumor component was diffusely or partially lost in 18 (81.8%) of 22 tested cases. Regarding the foci of lymph node metastasis, 13 (81.2%) of the 16 patients showed a significant loss of p16 expression. Loss of MTAP immunoexpression was observed less frequently compared with the loss of p16 expression. CDKN2A homozygous deletions were confirmed in all 5 tested cases by sequencing, whereas MTAP deletions were detected in only 2 cases. In conclusion, p16 expression loss and CDKN2A deletions can be frequently seen in invasive/metastatic cases of EMPD.
INTRODUCTION: Epidemiological transition to NCDs is a challenge for fragile health systems in the Caribbean. The Congregations Taking Action against NCDs (CONTACT) Study intervention proposes that trained health advocates (HAs) from places of worship (PoWs), supervised by nurses at nearby primary healthcare centres (PHCs), could facilitate access to primary care among vulnerable communities. Drawing on participatory and systems thinking, we explored the capacity of local PHCs in three Caribbean countries to support this intervention.
METHODS: Communities in Jamaica (rural, urban), Guyana (rural) and Dominica (Indigenous Kalinago Territory) were selected for CONTACT because of their differing socio-economic, cultural, religious and health system contexts. Through mixed-method concept mapping, we co-developed a list of perceived actionable priorities (possible intervention points ranked highly for feasibility and importance) with 48 policy actors, healthcare practitioners and civic society representatives. Guided in part by the concept mapping findings, we assessed the readiness of 12 purposefully selected PHCs for the intervention, using a staff questionnaire and an observation checklist to identify enablers and constrainers.
RESULTS: Concept mapping illustrated stakeholder optimism for the intervention, but revealed perceptions of inadequate primary healthcare service capacity, resources and staff training to support implementation. Readiness assessments of PHCs identified potential enablers and constrainers that were consistent with concept mapping results. Staff support was evident. Constraints included under-staffing, which could hinder supervision of HAs; and inadequate essential NCD medicines, training in NCDs and financial and policy support for embedding community interventions. Despite a history of socio-political disadvantage, the most enabling context was found in the Kalinago Territory, where ongoing community engagement activities could support joint development of programmes between churches and PHCs.
CONCLUSION: Multi-sectoral stakeholder consultation and direct PHC assessments revealed viability of the proposed POW-PHC partnership for NCD prevention and control. However, structural and policy support will be key for implementing change.
INTRODUCTION: Traditionally, using peripheral nerve blocks (PNBs) in patients with long bone fractures has been limited due to concerns that it may interfere with the timely diagnosis of acute compartment syndrome (ACS). However, our large academic institution and level I trauma center have been using regional anesthesia routinely for pain management of patients with long bone fractures for more than a decade, with strict adherence to a comprehensive management protocol. The aim of this retrospective review is to present our experience with this practice.
METHODS: Following Institutional Review Board approval, we performed a retrospective chart review of patients with long bone fractures and ACS over a 10-year period (2008-2018).
RESULTS: 26 537 patients were included in the review. Approximately 20% of these patients required surgery, and 91.5% of surgically treated patients received regional anesthesia. The incidence of ACS in our cohort was 0.1% or 1.017 per 1000 patients with long bone fractures.
CONCLUSION: Current recommendations on using PNBs in patients at risk for ACS have been mainly based on expert opinion and dated case reports. Due to the nature of the condition, prospective data are lacking. Our large observational dataset evaluated the risk of missing or delaying ACS diagnosis when PNBs were offered for trauma patients and demonstrated a relatively low incidence of ACS despite the routine use of PNBs under strictly protocolized conditions when patients were managed by a dedicated multidisciplinary care team.
Systems and methods for the selection, verification and recommendation of cohort sample sets is provided. In some embodiments, a dataset selection optimization includes first receiving at data stewards classes of data required by the data consumer. The data stewards process their data (or a subset of their data) into a vector set within a sequestered computing node. These vector sets are transferred to a core management system for minimizing a difference between a target vector and any combination of the data stewards' vector sets. A cost function may also be applied to the vector sets during this optimization. Once the data steward(s) that best match the target vector are identified, they may be placed in contact with the data consumer for access of their information.
Participants on the degarelix arm will receive a loading dose of degarelix 240 mcg subcutaneous 4-14 days before the start of pre-transplant conditioning. All participants will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 and no more than 48 hours prior to the start of cytoreduction.
The invention relates to the field of Chinese herbal medicines, and discloses a rubus chingii decoction piece. The rubus chingii decoction piece is prepared into granules or powder from mature rubus chingii fruit as a raw material. The invention also discloses a preparation method of the rubus chingii decoction piece. The preparation method of the rubus chingii decoction piece comprises the processes of selecting materials, dewatering in vacuum, crushing at low temperature, pelletizing, sterilizing and the like. The process is simple. The rubus chingii decoction piece disclosed by the invention can be swallowed, and also can be dissolved into cold or hot liquid to drink. Thus, the rubus chingii decoction piece is convenient to use. No chemical process exists in a preparation method of the rubus chingii decoction piece. Original ecology and nutrition ingredients of the mature rubus chingii are furthest reserved; the purity of the prepared rubus chingii granules can be up to 99% (1% of bonding material); and the purity of the powder can be up to 100%. According to the rubus chingii decoction piece disclosed by the invention, balanced sweetness and acidity, purple fruit, and strong and specific fruit flavor of the original mature rubus chingii fruit are reserved; and the rubus chingii decoction piece has the probiotic effects of resisting aging, preventing cancers, reducing frequent micturition caused by prostate, nourishing the liver and removing freckles, restraining gastritis and elytritis and the like.
The prospective randomized double blind study comprised 152 women who presented for the correction of stress urinary incontinence (SUI) in conjunction with anterior compartment pelvic organ prolapse stage II-III (POP-Q II-III) at the Departments of Obstetrics and Gynecology at the University of Szeged, Hungary, between June of 2016 and June 2017. After a block randomization method, the patients will divide into two arms, the study group which consist of 76 patients will undergo modified trans vaginal mesh operation (TVM), the rest 76 patients as a control group will undergo a traditional TVM operation. Inclusion criteria in the study is coexisting SUI and POP Q St II-III and signature of the informed consent. The exclusion criteria are as follows: urge, mixed or neurogenic incontinence, occult SUI, previous mesh operations, anti-depressive medical therapy, cancer of the pelvic organs, urinary infections, any sign of voiding difficulties. The transobturator TVM operation (Sergent et al.) has been modofied by inserting a stabilizing suture, which fixing the anterior edge of the mesh to the para-urethral tissues at the level of the mid-urethra with two non-resolvable anchoring stitches thereby promoting the proper elevation and closure of the urethra. The hypothesis is the stabilizing suture treat the coexisting SUI as well. In all cases, urodynamic examinations were carried out before the surgery and urodynamic examinations comprising uroflowmetry, cystography and Valsalva leak point pressure tests and pelvic floor ultrasonography will be performed to determine the coexisting SUI. The efficacy of the POP repair is taken as a significant (\>1 cm) improvement at points Aa, Ba, C and D according to the POP-Q system (International Continence Society) during the follow-up. The anti-incontinence efficacy is classified as no further SUI diagnosed by urodynamic examination and pelvic floor sonography. All patients will fill two validated Hungarian language questionnaires as "A short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire" (PISQ-12) and "Pelvic Floor Distress Inventory" PFDI. After a one-year application phase all patients will be followed for 36 months. During follow- up phase repeated urodynamic studies, pelvic floor sonography urine culturing will be done after 3, 12, 24 and 36 months. The evaluation of the POP-Q system and Bonney's cough test and the PISQ-12 and PFDI questionnaires will be performed at every regular check-ups
Natural extracts of spearmint and rosemary, together with hydrolyzed lecithin, are used to formulate a natural tinted moisturizer with more that 96% natural/nature-derived raw materials. Color pigments are suspended in the emulsion system thickened by xanthan gum. The process uses a combination of mixing with a homogenizer and a multi-speed stirrer. Stability is observed in accelerated conditions. The product results with an excellent emulsion stability. The hydrolyzed lecithin is liquid at room temperature. This study demonstrates that it is an easy to use emulsifier in cold-processed emulsions with a thickener system that can be dispersed and activated at room temperature. The hydrolyzed lecithin was used to emulsify blends of oils into a stable lotion for the cosmetic and personal care markets. The emulsion was found to be highly stable when centrifuged and studied at accelerated stability conditions
PURPOSE: To obtain a coating film composition showing the same excellent disintegration as that of a gelatin coating film without causing deterioration of disintegration under specific conditions in which a great amount of calcium ions exist. CONSTITUTION: This coating film composition for capsules comprises 18-28 pts.wt. hydroxypropylmethyl cellulose having 2.4-5.4 centistoke viscosity at 20 deg.C in 2% aqueous solution as a base, 0.01-0.1 pt.wt. carrageenan as a gelatinizing agent and 0.05-0.6 pt.wt. potassium ions or calcium ions or both as a gelatinizing auxiliary. Kappa-Carrageenan is preferable as the carrageenan and potassium ions as the gelatinizing auxiliary, respectively.
BACKGROUND: Luteolin is a natural flavonoid and its neuroprotective and anti-inflammatory effects have been confirmed to mitigate neurodegeneration. Despite these findings, the underlying mechanisms responsible for these effects remain unclear. Toll-like receptor 4 (TLR4) is widely distributed in microglia and plays a pivotal role in neuroinflammation and neurodegeneration. Here studies are outlined that aimed at determining the mechanisms responsible for the anti-inflammatory and neuroprotective actions of luteolin using a rodent model of Parkinson's disease (PD) and specifically focusing on the role of TLR4 in this process.
METHODS: The mouse model of PD used in this experiment was established through a single injection of lipopolysaccharide (LPS). Mice were then subsequently randomly allocated to either the luteolin or vehicle-treated group, then motor performance and dopaminergic neuronal injury were evaluated. BV2 microglial cells were treated with luteolin or vehicle saline prior to LPS challenge. MRNA expression of microglial specific marker ionized calcium-binding adapter molecule 1 (IBA-1) and M1/M2 polarization markers, as well as the abundance of indicated pro-inflammatory cytokines in the mesencephalic tissue and BV2 were quantified by real time-polymerase chain reaction (RT-PCR) and Enzyme-linked Immunosorbent Assay (ELISA), respectively. Cell viability and apoptosis of neuron-like PC12 cell line co-cultured with BV2 were detected. TLR4 RNA transcript and protein abundance in mesencephalic tissue and BV2 cells were detected. Nuclear factor kappa-gene binding (NF-κB) p65 subunit phosphorylation both in vitro and in vivo was evaluated by immunoblotting.
RESULTS: Luteolin treatment induced functional improvements and alleviated dopaminergic neuronal loss in the PD model. Luteolin inhibited apoptosis and promoted cell survival in PC12 cells. Luteolin treatment shifted microglial M1/M2 polarization towards an anti-inflammatory M2 phenotype both in vitro and in vivo. Finally, it was found that luteolin treatment significantly downregulated both TLR4 mRNA and protein expression as well as restraining NF-κB p65 subunit phosphorylation.
CONCLUSIONS: Luteolin restrained dopaminergic degeneration in vitro and in vivo by blocking TLR4-mediated neuroinflammation.
All subjects undergo the same procedures. Subjects will be subjected to measurements on the IMD (Working Model 3.4NR), FreeStyle Libre, Dexcom, microdialysis, venous and capillary blood collection.